Alan Landay to Antiretroviral Therapy, Highly Active
This is a "connection" page, showing publications Alan Landay has written about Antiretroviral Therapy, Highly Active.
Connection Strength
4.274
-
Short communication: Apoptosis pathways in HIV-1-infected patients before and after highly active antiretroviral therapy: relevance to immune recovery. AIDS Res Hum Retroviruses. 2015 Feb; 31(2):208-16.
Score: 0.489
-
Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy. J Infect Dis. 2010 Jun 15; 201(12):1796-805.
Score: 0.360
-
Evaluation of the impact of highly active antiretroviral therapy on immune recovery in antiretroviral naive patients. HIV Med. 2004 Jan; 5(1):55-65.
Score: 0.230
-
CCR5 and CXCR4 expression after highly active antiretroviral therapy (HAART). J Acquir Immune Defic Syndr. 2002 Aug 01; 30(4):458-60.
Score: 0.209
-
HIV and Aging in the Era of ART and COVID-19: Symposium Overview. J Acquir Immune Defic Syndr. 2022 02 01; 89(Suppl 1):S3-S9.
Score: 0.202
-
Persistence of intracellular HIV-1 mRNA correlates with HIV-1-specific immune responses in infected subjects on stable HAART. AIDS. 2001 Sep 07; 15(13):1635-41.
Score: 0.196
-
Differences in serum IgA responses to HIV-1 gp41 in elite controllers compared to viral suppressors on highly active antiretroviral therapy. PLoS One. 2017; 12(7):e0180245.
Score: 0.147
-
Rifaximin has a marginal impact on microbial translocation, T-cell activation and inflammation in HIV-positive immune non-responders to antiretroviral therapy - ACTG A5286. J Infect Dis. 2015 Mar 01; 211(5):780-90.
Score: 0.121
-
HIV RNA levels in plasma and cervical-vaginal lavage fluid in elite controllers and HAART recipients. AIDS. 2014 Mar 13; 28(5):739-43.
Score: 0.117
-
Treatment-related changes in serum lipids and inflammation: clinical relevance remains unclear. Analyses from the Women's Interagency HIV study. AIDS. 2013 Jun 01; 27(9):1516-9.
Score: 0.111
-
Towards an HIV cure: a global scientific strategy. Nat Rev Immunol. 2012 07 20; 12(8):607-14.
Score: 0.104
-
A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4? T-cell recovery despite sustained virologic suppression: ACTG A5256. J Infect Dis. 2012 Aug 15; 206(4):534-42.
Score: 0.104
-
The effect of HIV infection and HAART on inflammatory biomarkers in a population-based cohort of women. AIDS. 2011 Sep 24; 25(15):1823-32.
Score: 0.098
-
Early immune senescence in HIV disease. Curr HIV/AIDS Rep. 2010 Feb; 7(1):4-10.
Score: 0.088
-
Delaying a treatment switch in antiretroviral-treated HIV type 1-infected patients with detectable drug-resistant viremia does not have a profound effect on immune parameters: AIDS Clinical Trials Group Study A5115. AIDS Res Hum Retroviruses. 2009 Feb; 25(2):135-9.
Score: 0.082
-
Neurodegeneration and ageing in the HAART era. J Neuroimmune Pharmacol. 2009 Jun; 4(2):163-74.
Score: 0.081
-
Characterization of quantitative and functional innate immune parameters in HIV-1-infected Colombian children receiving stable highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2008 Dec 01; 49(4):348-57.
Score: 0.081
-
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. AIDS. 2008 Jun 19; 22(10):1131-5.
Score: 0.078
-
Invariant NKT cells from HIV-1 or Mycobacterium tuberculosis-infected patients express an activated phenotype. Clin Immunol. 2008 Apr; 127(1):1-6.
Score: 0.077
-
The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328. Arch Intern Med. 2007 Mar 26; 167(6):597-605.
Score: 0.072
-
Immunogenetics of CD4 lymphocyte count recovery during antiretroviral therapy: An AIDS Clinical Trials Group study. J Infect Dis. 2006 Oct 15; 194(8):1098-107.
Score: 0.069
-
Long-term changes in circulating CD4 T lymphocytes in virologically suppressed patients after 6 years of highly active antiretroviral therapy. AIDS. 2004 Sep 24; 18(14):1953-6.
Score: 0.061
-
Proliferation responses to HIVp24 during antiretroviral therapy do not reflect improved immune phenotype or function. AIDS. 2004 Mar 05; 18(4):605-13.
Score: 0.058
-
Recent observations on HIV type-1 infection in the genital tract of men and women. AIDS. 2003 Mar 07; 17(4):455-80.
Score: 0.054
-
T cell responses to recall antigens, alloantigen, and mitogen of HIV-infected patients receiving long-term combined antiretroviral therapy. AIDS Res Hum Retroviruses. 2000 Nov 20; 16(17):1887-93.
Score: 0.046
-
Normalization of immune activation in lymphoid tissue following highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2000 Oct 01; 25(2):150-6.
Score: 0.046
-
A look at HIV immune research. Interview by Alan Huff. Res Initiat Treat Action. 2000 Sep; 6(3):30-3.
Score: 0.046
-
Presence of asymptomatic cytomegalovirus and Epstein--Barr virus DNA in blood of persons with HIV starting antiretroviral therapy is associated with non-AIDS clinical events. AIDS. 2020 05 01; 34(6):849-857.
Score: 0.045
-
Sialylation and fucosylation modulate inflammasome-activating eIF2 Signaling and microbial translocation during HIV infection. Mucosal Immunol. 2020 09; 13(5):753-766.
Score: 0.044
-
Delayed gastrointestinal-associated lymphoid tissue reconstitution in duodenum compared with rectum in HIV-infected patients initiating antiretroviral therapy. AIDS. 2019 12 01; 33(15):2289-2298.
Score: 0.043
-
A Randomized, Double-blinded, Placebo-controlled Trial of Sitagliptin for Reducing Inflammation and Immune Activation in Treated and Suppressed Human Immunodeficiency Virus Infection. Clin Infect Dis. 2019 09 13; 69(7):1165-1172.
Score: 0.043
-
Loss of CXCR4 on non-classical monocytes in participants of the Women's Interagency HIV Study (WIHS) with subclinical atherosclerosis. Cardiovasc Res. 2019 05 01; 115(6):1029-1040.
Score: 0.042
-
Vitamin D does not modulate immune-mediated bone loss during ART initiation. Antivir Ther. 2019; 24(5):355-362.
Score: 0.041
-
Higher Anti-Cytomegalovirus Immunoglobulin G Concentrations Are Associated With Worse Neurocognitive Performance During Suppressive Antiretroviral Therapy. Clin Infect Dis. 2018 08 16; 67(5):770-777.
Score: 0.040
-
Higher Body Mass Index Is Associated With Greater Proportions of Effector CD8+ T Cells Expressing CD57 in Women Living With HIV. J Acquir Immune Defic Syndr. 2017 08 15; 75(5):e132-e141.
Score: 0.037
-
Impact of Hepatitis C Virus on the Circulating Levels of IL-7 in HIV-1 Coinfected Women. J Acquir Immune Defic Syndr. 2016 Feb 01; 71(2):172-80.
Score: 0.033
-
Characterization of CD4? T-cell immune activation and interleukin 10 levels among HIV, hepatitis C virus, and HIV/HCV-coinfected patients. J Acquir Immune Defic Syndr. 2013 Nov 01; 64(3):232-40.
Score: 0.028
-
Association of subclinical atherosclerosis with lipid levels amongst antiretroviral-treated and untreated HIV-infected women in the Women's Interagency HIV study. Atherosclerosis. 2012 Dec; 225(2):408-11.
Score: 0.026
-
Interleukin 10 responses are associated with sustained CD4 T-cell counts in treated HIV infection. J Infect Dis. 2012 Sep 01; 206(5):780-9.
Score: 0.026
-
CD28-negative CD4+ and CD8+ T cells in antiretroviral therapy-naive HIV-infected adults enrolled in adult clinical trials group studies. J Infect Dis. 2012 Jun; 205(11):1730-8.
Score: 0.025
-
HIV infection and aging of the innate immune system. Sex Health. 2011 Dec; 8(4):453-64.
Score: 0.025
-
A randomized trial of interleukin-2 during withdrawal of antiretroviral treatment. J Interferon Cytokine Res. 2011 Jun; 31(6):481-3.
Score: 0.024
-
HIV-1 viruses detected during episodic blips following interleukin-7 administration are similar to the viruses present before and after interleukin-7 therapy. AIDS. 2011 Jan 14; 25(2):159-64.
Score: 0.023
-
Inflammatory biomarkers and abacavir use in the Women's Interagency HIV Study and the Multicenter AIDS Cohort Study. AIDS. 2010 Jul 17; 24(11):1657-65.
Score: 0.023
-
Comparison of immunologic assays for detecting immune responses in HIV immunotherapeutic studies: AIDS Clinical Trials Group Trial A5181. Clin Vaccine Immunol. 2010 Sep; 17(9):1452-9.
Score: 0.023
-
Age-related changes in plasma concentrations of the HIV protease inhibitor lopinavir. AIDS Res Hum Retroviruses. 2010 Jun; 26(6):635-43.
Score: 0.022
-
Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis. 2009 Apr 15; 199(8):1177-85.
Score: 0.021
-
GBV-C viremia is associated with reduced CD4 expansion in HIV-infected people receiving HAART and interleukin-2 therapy. AIDS. 2009 Mar 13; 23(5):605-10.
Score: 0.021
-
Enhanced antibody responses elicited by a CpG adjuvant do not improve the protective effect of an aldrithiol-2-inactivated simian immunodeficiency virus therapeutic AIDS vaccine. Clin Vaccine Immunol. 2009 Apr; 16(4):499-505.
Score: 0.021
-
PDL-1 upregulation on monocytes and T cells by HIV via type I interferon: restricted expression of type I interferon receptor by CCR5-expressing leukocytes. Clin Immunol. 2008 Oct; 129(1):132-44.
Score: 0.020
-
Reducing the burden of HIV/AIDS in infants: the contribution of improved diagnostics. Nature. 2006 Nov 23; 444 Suppl 1:19-28.
Score: 0.018
-
Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006 Dec; 12(12):1365-71.
Score: 0.018
-
Evaluating the impact of hepatitis C virus (HCV) on highly active antiretroviral therapy-mediated immune responses in HCV/HIV-coinfected women: role of HCV on expression of primed/memory T cells. J Infect Dis. 2006 May 01; 193(9):1202-10.
Score: 0.017
-
Distinct mechanisms of T cell reconstitution can be identified by estimating thymic volume in adult HIV-1 disease. J Infect Dis. 2005 Nov 01; 192(9):1577-87.
Score: 0.016
-
Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet. 2005 Aug 13-19; 366(9485):549-55.
Score: 0.016
-
HIV-1-infected antiretroviral-treated patients with prolonged partial viral suppression: clinical, virologic, and immunologic course. J Acquir Immune Defic Syndr. 2003 Dec 15; 34(5):491-6.
Score: 0.014
-
Can immune markers predict subsequent discordance between immunologic and virologic responses to antiretroviral therapy? Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003 Aug 15; 37(4):551-8.
Score: 0.014
-
Interleukin-2 Increases CD4+ lymphocyte numbers but does not enhance responses to immunization: results of A5046s. J Infect Dis. 2003 Jan 15; 187(2):320-5.
Score: 0.013
-
Effect of etanercept (Enbrel) on interleukin 6, tumor necrosis factor alpha, and markers of immune activation in HIV-infected subjects receiving interleukin 2. AIDS Res Hum Retroviruses. 2002 Jun 10; 18(9):661-5.
Score: 0.013
-
Multiple CD4+ cell kinetic patterns and their relationships with baseline factors and virological responses in HIV type 1 patients receiving highly active antiretroviral therapy. AIDS Res Hum Retroviruses. 2001 Sep 01; 17(13):1231-40.
Score: 0.012